The Tianjin, China-based company, which was the first to move a vaccine into Phase II development, also became the first to published peer-reviewed data, from its Phase I study. Moderna released preliminary data this week, but it was seen as too early for interpreting its vaccine's efficacy.
The Tianjin, China-based company and a Canadian federal research institution plan to advance bioprocessing and clinical development of Ad5-nCoV in Canada. CanSinoBIO is currently running a Phase II clinical trial in China.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
The company said in a regulatory filing that it plans to enter Phase II development "soon" and on Friday had already posted a page for the study, which will take place in China, on ClinicalTrials.gov. Moderna plans to enter Phase II development in spring or early summer.